GPT and Hepatic fibrosis: Notably, despite significant accumulation of P-G3 Lyp1 in the liver (Fig. 2H), no adverse effects were observed in assessing hepatic lipid content, liver fibrosis (Fig. 2I), or hepatoxicity, as measured by serum alanine aminotransferase (ALT) (Fig. 2J).